Access broad and deep neurology expertise to reduce costs, accelerate timelines and manage risk, from clinical trials to evidence generation and beyond.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSCurrently, an estimated 5.5 million Americans are living with dementia due to Alzheimer’s disease (AD).1 In 2017, the disease will cost the U.S. an estimated $259B, of which drug costs are only ~$2B.1,2
By comparison, there were roughly 1.7 million new cancer patients in the U.S. in 2016, and drug costs associated with all cancers cost the U.S. a combined ~$50B.2,3 As the population ages, the prevalence of AD is expected to grow substantially, roughly tripling to nearly 14 million U.S. patients by 2050.1 Falling agespecific risks of dementia (as seen in some high-income countries over the last 25 years)4 may relieve some of this future burden, but the overall growth of the elderly population will still lead to a large patient pool. In addition, AD is becoming a more common cause of death. Death records indicate that mortality attributed to AD has increased 89% between 2000 and 2014, while other leading causes of death like heart disease and stroke have consistently declined.1 Meanwhile, current treatments for AD target only symptoms and fail to slow the progression of disease.
However, change may be on the horizon. Despite the recent failure of solanezumab,5 verubecestat6 and others, investment in clinical trials in AD is at an all-time high.7 Promising results of other agents, such as aducanumab, suggest that we may be closer than ever to the approval of a Disease Modifying Therapy (DMT) in AD.*
Given this potential for transformative change, it is more important than ever to consider whether the current healthcare system is developed enough to deliver the full benefit of such a treatment. We believe the answer is no, and we have identified five key challenges that stakeholders across the system – policy makers, providers, pharma, caregivers, patients and patient associations – will need to solve together in order to successfully realize the full benefit of a DMT.
Access broad and deep neurology expertise to reduce costs, accelerate timelines and manage risk, from clinical trials to evidence generation and beyond.